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Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and
lymphocyte chemotaxis, while preserving antiangiogenic properties
Paul Proost, Evemie Schutyser, Patricia Menten, Soﬁe Struyf, Anja Wuyts, Ghislain Opdenakker, Michel Detheux, Marc Parmentier,
Christine Durinx, Anne-Marie Lambeir, Johan Neyts, Sandra Liekens, Prabhat C. Maudgal, Alfons Billiau, and Jo Van Damme
The interferon (IFN)–inducible chemo-
kines, speciﬁcally, IFN-g–inducible pro-
tein-10(IP-10),monokineinducedbyIFN-g
(Mig),andIFN-inducibleT-cella-chemoat-
tractant (I-TAC), share a unique CXC che-
mokine receptor (CXCR3). Recently, the
highly speciﬁc membrane-bound pro-
tease and lymphocyte surface marker
CD26/dipeptidylpeptidaseIV(DPPIV)was
found to be responsible for posttransla-
tional processing of chemokines. Re-
movalofNH2-terminaldipeptidesbyCD26/
DPPIV alters chemokine receptor binding
and signaling, and hence inﬂammatory
and anti–human immunodeﬁciency virus
(HIV) activities. CD26/DPP IV and CXCR3
are both markers for Th1 lymphocytes
and, moreover, CD26/DPP IV is present in
a soluble, active form in human plasma.
This study reports that at physiologic
enzyme concentrations CD26/DPP IV
cleaved 50% of I-TAC within 2 minutes,
whereas for IP-10 and Mig the kinetics
were 3- and 10-fold slower, respectively.
Processing of IP-10 and I-TAC by CD26/
DPP IV resulted in reduced CXCR3-bind-
ing properties, loss of calcium-signaling
capacity through CXCR3, and more than
10-fold reduced chemotactic potency.
Moreover, IP-10 and I-TAC cleaved by
CD26/DPPIVactedaschemotaxisantago-
nists and CD26/DPP IV–truncated IP-10
and Mig retained their ability to inhibit the
angiogenic activity of interleukin-8 in the
rabbit cornea micropocket model. These
data demonstrate a negative feedback
regulation by CD26/DPP IV in CXCR3-
mediated chemotaxis without affecting
the angiostatic potential of the CXCR3
ligands IP-10 and Mig. (Blood. 2001;98:
3554-3561)
© 2001 by TheAmerican Society of Hematology
Introduction
Chemokines constitute a family of low molecular mass proteins
that regulate the directed migration of speciﬁc subclasses of
leukocytes during normal and inﬂammatory processes.1-3 The
cellular speciﬁcity of chemokines is determined by the restricted
expression of chemokine receptors on various leukocyte cell
types.4 Chemokines are divided into subfamilies depending on the
position of the ﬁrst 2 cysteines in their primary sequence. The CC
subfamily, with 2 adjacent cysteines, contains more than 20
different proteins that regulate the migration of monocytes, eosino-
phils, basophils, B and T lymphocytes, natural killer (NK) cells,
and dendritic cells. The CXC chemokine subfamily, with 2
cysteines separated by one other amino acid, contains several
proteins with a Glu-Leu-Arg (ELR) motif in front of the ﬁrst
cysteine. These ELRCXC chemokines all attract neutrophilic
granulocytes to sites of inﬂammation. The CXC chemokines
without an ELR motif can attract monocytes and B or T lympho-
cytes. Three of the known non-ELRCXC chemokines, speciﬁcally,
interferon-g (IFN-g)–inducible protein-10 (IP-10 or CXCL10),
monokine induced by IFN-g (Mig or CXCL9), and IFN-inducible
T-cell a-chemoattractant (I-TAC or CXCL11) recognize a single
CXC chemokine receptor (CXCR), namely CXCR3.5-8 IP-10, Mig,
and I-TAC attract monocytes and activated memory Th1, but not
Th2, lymphocytes.9-11 Furthermore, eosinophils and subclasses of
B and NK cells express CXCR3.11,12 In addition to their role in
leukocyte migration, chemokines play a role in angiogenesis.13-16
CXCR2 is an important receptor for the angiogenic activity of
ELRCXC chemokines.17,18 In contrast, the molecular mechanism
underlying the angiostatic activity of the non-ELRCXC chemo-
kines IP-10, Mig, and platelet factor 4 (PF-4 or CXCL4) is not
completely understood.15 In addition to CXCR1 and CXCR2 (both
receptors for angiogenic ELRCXC chemokines), CXCR3 (the
receptor for the angiostatic chemokines IP-10 and Mig) has also
been detected on microvascular endothelial cells.19 Recently,
expression of CXCR3 on microvascular endothelial cells has been
reportedtobedependentonthecellcycle.20Proliferatingmicrovas-
cular endothelial cells in the S/G2-M phase of their cell cycle
express CXCR3. Moreover, Mig and IP-10 inhibited endothelial
cell proliferation in vitro. These ﬁndings point to a possible
down-regulatory role for CXCR3 in angiogenic processes.
The NH2-terminal region of most chemokines is crucial for
receptor binding and signaling activities. Some chemokines be-
come chemotactic only when processed at the NH2-terminus, for
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(CXCL7).21 Others, for example, the monocyte chemotactic pro-
teins MCP-1 (CCL2), MCP-2 (CCL8), and MCP-3 (CCL7), lose
their chemotactic activity when NH2-terminal amino acids are
cleaved off.22,23 Aminopeptidases or endopeptidases that process
chemokines at the NH2-terminus play an important role in the
up-regulation or down-regulation of chemokine activities. One of
these enzymes, the membrane-associated protease dipeptidyl pepti-
dase IV (DPP IV, EC3.4.14.5) is highly speciﬁc. It cleaves off
dipeptidesfrompolypeptideswithaproline,alanine,orhydroxypro-
line at the second position. DPP IV, which is expressed on
ﬁbroblasts and epithelial and endothelial cells, is identical to the
lymphocyte surface glycoprotein and T-cell activation marker
CD26.24 The extracellular domain of CD26/DPPIV also exists as a
soluble and proteolytically active form in plasma and in cerebrospi-
nal and seminal ﬂuids. CD26/DPP IV interacts with CD45 (a
protein tyrosine phosphatase) and with adenosine deaminase, has
costimulatory activity in T-cell immune responses, plays a role in
immune processes such as allograft rejection, suppresses malignant
transformation, and has been implicated in the regulation of insulin
secretion.24,25 Recently, CD26/DPP IV was found to cleave a
number of chemokines, but not cytokines.26 For example, removal
by CD26/DPP IV of the 2 NH2-terminal amino acids from stromal
cell–derived factor-1 (SDF-1 or CXCL12) resulted in signiﬁcantly
reduced chemotactic and calcium-signaling activity due to a
decreased afﬁnity for CXC chemokine receptor 4 (CXCR4).27,28
Accordingly, SDF-1(3-68) processed by CD26/DPP IV lacks
antiviral activity against T-tropic human immunodeﬁciency virus
type 1 (HIV-1) strains.
CD26 is highly expressed on Th1 cells and its expression is
up-regulated by IFN-g, a typical Th1 cytokine.29 Moreover, one of
the chemokine receptors that has been identiﬁed as a Th1 cell
marker, in addition to CCR5, is CXCR3.9-11 Here we report that
CD26/DPP IV efﬁciently cleaved all 3 CXCR3 ligands and
demonstrate that the protease differently affects the receptor
signaling, lymphocyte chemotactic, and antiangiogenic activities
of these chemokines.
Materials and methods
Reagents and cell lines
Recombinant human chemokines, that is, IP-10, Met-IP-10 (IP-10 includ-
ing an extra NH2-terminal methionine), Mig, and I-TAC and recombinant
human interleukin-2 (IL-2) were purchased from PeproTech (Rocky Hill,
N J )o rR&DSystems (Abingdon, United Kingdom). Natural IL-8 was
puriﬁed to homogeneity from conditioned medium of monocytes and
contained an equimolar mixture of IL-8(1-77), IL-8(5-77) and IL-8(6-77).21
Soluble natural human CD26/DPP IV, without membrane anchor and
starting at amino acid Gly31, was obtained from total seminal plasma and
puriﬁed to homogeneity by anion exchange followed by afﬁnity chromatog-
raphy on immobilized adenosine deaminase as described.30 Human CXCR3
was stably expressed in Chinese hamster ovary K1 (CHO-K1) cells
(American Type Culture Collection [ATCC], Manassas, VA: CCL-61) and
the cells were cultured in HAM F-12 medium (Biowhittaker Europe,
Verviers, Belgium) supplemented with 10% fetal bovine serum (FBS), 1
mM sodium pyruvate, and 400 mg/mLgeneticin.
In vitro truncation of chemokines by CD26/DPP IV
To obtain efﬁcient truncation, chemokines were treated with soluble
CD26/DPP IV for 18 hours at 37°C. Subsequently, they were subjected to
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
as previously described.31 NH2-terminal truncation was veriﬁed by Edman
degradation on a pulsed liquid phase 477A/120Aor Procise 491cLC protein
sequencer after electroblotting 0.5 to 2 mg processed chemokine from the
gel to Problot membranes (Applied Biosystems, Foster City, CA). Alterna-
tively, truncated chemokines were puriﬁed by C8 reverse-phase high-
performance liquid chromatography (RP-HPLC) on a Brownlee Aquapore
RP-300 column (50 3 1 mm; PerkinElmer, Norwalk, CT) and the average
Mr was determined by electrospray ion trap mass spectrometry (Esquire-
LC; Bruker Daltonic, Bremen, Germany).
To determine the time course of the NH2-terminal truncation, IP-10,
Mig, and I-TAC (5 mM) were incubated with soluble CD26/DPP IV (250,
25, 2.5, and 0.25 U/L) in 15 mL 50 mM Tris buffer, pH 7.5, supplemented
with 1 mM EDTA. The speciﬁcity of the reaction was checked by
incubating the chemokines with Tris buffer alone. Samples (5 mL) were
withdrawn after 5, 15, and 30 minutes, and the reaction was stopped by
addition of triﬂuoroacetic acid (ﬁnal concentration of 0.1%). The samples
were desalted on a C18 ZipTip (Millipore, Bedford, MA) and the relative
amounts of the NH2-terminally truncated chemokines were determined by
ion trap mass spectrometry. The time course of the truncation (shown in
Figure 1) was constructed by normalizing the incubation times, taking into
account that 25 U/Lis close to the normal serum concentration of DPPIV.32
Chemotaxis assays
Peripheral blood mononuclear cells were puriﬁed from buffy coats from
healthy volunteers as previously described.33 Mononuclear cells were
stimulated with anti-CD3 antibodies (OKT3: ATCC CRL-8001) in RPMI
1640 (Biowhittaker Europe) with 10% FBS for 2 days before use.
Alternatively, mononuclear cells were cultured in RPMI 1640 with 10%
FBS and treated with phytohemagglutinin (PHA; 2 mg/mL) for 3 days,
washed with RPMI 1640, and kept in culture for 2 to 3 weeks in RPMI 1640
supplemented with 10% FBS and 50 U/mL IL-2 before use in the
chemotaxis assay.7
Lymphocyte chemotaxis was performed in Boyden microchambers
(Neuro Probe, Cabin John, MD) with ﬁbronectin-coated, polyvinylpyrroli-
done-free polycarbonate membranes (5-mm pore size, Corning Separations
Division, Acton, MA). Lymphocytes were suspended in Hanks balanced
salt solution (HBSS) plus 0.1% (wt/vol) human serum albumin (HSA) at
2 3 106 cells/mL and were allowed to migrate for 2 hours at 37°C. Before
chemotaxis, CXCR3-transfected CHO cells were resuspended in HBSS
plus 0.1% HSA and diluted to 1.5 3 106 cells/mL. Boyden chamber
chemotaxis experiments were performed for 2 hours at 37°C with 8-mm
pore size polyvinylpyrrolidone-free polycarbonate membranes. To study
antagonism, truncated chemokines were added at inactive concentrations
together with the active substance to the bottom well of the Boyden
chambers. Cells that migrated through the membrane were stained with
DiffQuick (Merck, Darmstadt, Germany) and counted microscopically in
10 oil immersion ﬁelds (3 500 magniﬁcation). The chemotactic index was
calculated as the number of cells migrated to the sample divided by the
number of cells spontaneously migrated to the sample dilution medium
(HBSS 1 0.1% HSA).
Calcium-signaling and receptor-binding assays
Alterations in intracellular calcium concentration ([Ca11]i) in response to
chemokinesweremonitoredbyﬂuorescencespectrometry.Brieﬂy,CXCR3-
transfected cells were loaded with the ﬂuorescent dye Fura-2-AM for 30
minutes at room temperature as previously described.31 Cells were washed
with buffer containing 125 mM probenecid (ICN Biomedicals, Costa Mesa,
CA), kept at 4°C, and preincubated for 10 minutes at 31°C before use.
[Ca11]i were measured in an LS50B spectroﬂuorimeter (PerkinElmer) at a
ﬁnal cell concentration of 106 cells/mL in buffer containing 125 mM
probenecid. During desensitization experiments, CD26/DPP IV–truncated
CXCR3-ligands were ﬁrst added at inactive concentrations followed by
intact CXCR3 ligands. The increase in [Ca11]i after desensitization with
the truncated chemokines was compared with the increase in [Ca11]i after
the addition of an equal amount of dilution buffer to calculate the
percentage desensitization.
Competition for 125I-labeled I-TAC binding was measured on freshly
isolated peripheral blood mononuclear cells or on CXCR3-transfected cells
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0.06 nM 125I I-TAC (Amersham Pharmacia Biotech, Uppsala, Sweden) and
varying concentrations of unlabeled chemokine. Cells were centrifuged and
washed 3 times with 2 mL phosphate-buffered saline (PBS) supplemented
with 2% (wt/vol) bovine serum albumin (BSA) and the radioactivity present
on the cells was measured in a gamma counter.
In vivo test for antiangiogenic activity of chemokines
Chemokines were tested for their angiogenic or angiostatic activity in the
rabbit cornea micropocket model.16 Brieﬂy, 32 mg sucralfate (Merck) was
dissolved in 72 mL PBS. Then, 4 mL of this sucralfate solution was mixed
with 4 mL Hydron solution (12% Hydron in ethanol; Interferon Sciences,
New Brunswick, NJ) and 5-mL pellets were allowed to dry under UV light
for 20 minutes. Subsequently, different concentrations of chemokines or
dilution buffer (negative control) were dried on the pellets. One pellet was
implanted 1 mm from the limbus into a corneal micropocket of each eye of
an anesthetized New Zealand white rabbit. Neovascularization of the
cornea was scored daily from day 4 to day 8 after implantation of the pellet.
Maximal neovascularization was obtained between days 5 and 7. This
maximal neovascularization was used for comparison.
Results
Processing of CXCR3 ligands by CD26/DPP IV
The NH2-terminal sequence analysis on commercially available
recombinant IP-10 from various companies revealed that most
proteins contained an extra methionine at the NH2-terminus
(Met-IP-10). Automated Edman degradation on Mig and I-TAC
(derived from PeproTech or R&D Systems), and on IP-10 from a
batch without NH2-terminal methionine (PeproTech), conﬁrmed
the correct NH2-terminus for these recombinant chemokines (Table
1). Incubation of IP-10, I-TAC, and Mig with CD26/DPP IV
resulted in the effective removal (. 95%) of the NH2-terminal
dipeptide. After 18 hours of incubation with CD26/DPP IV, no
remaining intact chemokine was detectable by Edman degradation.
Proteolysis beyond the penultimate proline or proteolysis of
Met-IP-10 was not observed, conﬁrming the purity and speciﬁcity
of CD26/DPP IV. For biologic evaluation, proteolytically cleaved
CXCR3 ligands were puriﬁed by C8 RP-HPLC. The purity and Mr
of the cleaved chemokines were conﬁrmed by mass spectrometry,
which excludes carboxy-terminal or internal processing (Table 1).
Mass spectrometry was used to study the time course of
chemokine processing (Figure 1).When 5 mM IP-10 was incubated
with serum concentrations (25 U/L) of CD26/DPP IV, 50% of the
chemokine was truncated within the ﬁrst 5 minutes and after 20
minutes less than 10% of the IP-10 proteins remained intact. In
contrast, the kinetics of Mig processing were about 4 times slower
(50% conversion in 20 minutes) than that of IP-10, whereas 50%
and 90% of intact I-TAC was converted into I-TAC(3-73) within
1.5 and 6 minutes, respectively. Thus, CD26/DPP IV processed
I-TAC more than 10-fold faster than Mig.
Impaired lymphocyte chemotactic activity of IP-10 after
CD26/DPP IV cleavage
The chemotactic activity of Met-IP-10 and intact and CD26/DPP
IV–truncated IP-10 was compared on activated (by PHA or
anti-CD3) lymphocytes. A dose-dependent chemotactic effect was
obtained with intact IP-10 from 1 nM onward on PHA-stimulated
lymphocytes (Figure 2A). Compared to IP-10(1-77), about 3-fold
higher concentrations of Met-IP-10 were required for a comparable
chemotactic response. IP-10(3-77), however, was still inactive at
concentrations as high as 10 nM. Thus, processing of IP-10 by
CD26/DPP IV resulted in a 30-fold reduction in lymphocyte
chemotactic activity. Similar results were observed with truncated
compared to intact IP-10 on anti-CD3–activated lymphocytes
(Figure 2B), although these cells were less sensitive to IP-10–
inducedchemotaxisthanPHA-stimulatedlymphocytes.Thisobser-
vation correlates with the reported lower expression of CXCR3 on
anti-CD3–stimulated cells.5
Figure 1. Time course of the truncation of CXCR3 ligands by CD26/DPPIV. IP-10
(diamonds), Mig (circles), and I-TAC (triangles) at 5 mM were incubated for different
time intervals with 25 U/L soluble CD26/DPP IV as indicated in “Materials and
methods.” The remaining concentration of the intact CXCR3 ligands determined by
mass spectrometry is indicated in the graphs.
Table 1. NH2-terminal sequence analysis and mass spectrometry of CD26/DPP IV–treated chemokines
Chemokine
NH2-terminal sequence* Reduction in Mr
Untreated CD26/DPP IV–treated Theoretical Observed†
Met-IP-10 MVPLSRTVRCTC MVPLSRTVRCTC 0 0
IP-10 VPLSRTVRCTC LSRTVRCTC 196.25 196.9 6 0.4
Mig TPVVRKGRCSC VVRKGRCSC 198.22 197.7 6 0.4
I-TAC FPMFKRGRCLC MFKRGRCLC 244.29 243.9 6 0.3
Single-letter amino acid abbreviations used.
*The NH2-terminal sequence of untreated and CD26/DPP IV–treated (18-hour incubation) chemokines was determined by automated Edman degradation.
†The average (6 SD) difference between the Mr of intact and truncated CXCR3 ligands was calculated from mass measurements on 4 different incubations (between 2
and 30 minutes) with CD26/DPP IV (25 U/L).
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signaling capacities of IP-10, Mig, and I-TAC on
CXCR3-transfected cells
Only one receptor for IP-10, that is, CXCR3, has been identiﬁed.6
Therefore, the chemotactic potencies of Met-IP-10, IP-10(1-77)
and IP-10(3-77) were compared on CHO cells transfected with
CXCR3 (Figure 3). For IP-10, a dose-dependent (minimal effective
concentration of 3 nM) chemotactic response was observed,
whereas for CD26/DPP IV–truncated IP-10(3-77) the minimal
effective concentration (100 nM) was 30-fold higher. Even at 100
nM, Met-IP-10 failed to induce a signiﬁcant chemotactic response.
Intact Mig and I-TAC induced a signiﬁcant chemotactic response
on CXCR3-transfected cells at 10 nM (P , .01). In contrast,
truncated Mig(3-103) and I-TAC(3-73) were inactive at concentra-
tions as high as 100 nM.Although their NH2-terminal amino acid is
different, removal of 2 amino acids (including the penultimate
proline) resulted in a similarly impaired chemotactic activity of all
3 CXCR3 agonists.
Furthermore, it was observed that intact IP-10 and I-TAC
induced a signiﬁcant increase in [Ca11]i at concentrations higher
than 0.3 nM, whereas 30-fold higher concentrations of Mig were
required to obtain a detectable calcium response in CXCR3-
transfected CHO cells (Figure 4). Met-IP-10 was about 3-fold less
potent compared to IP-10(1-77) and CD26/DPP IV–truncated
IP-10 lacked the calcium-signaling capacity through CXCR3.
Indeed, although intact IP-10 induced calcium mobilization at 1
nM, IP-10(3-77) was inactive in the calcium assay at concentra-
tions as high as 60 nM. Truncation of I-TAC by CD26/DPP IV
resulted in a 30- to 100-fold reduced calcium signaling capacity for
this CXCR3 ligand. In contrast, no signiﬁcant reduction in the
weak calcium mobilizing capacity of Mig through CXCR3 could
be observed for Mig(3-103). In conclusion, although none of
the 3 ligands possessed CXCR3-mediated chemotactic activity
after NH2-terminal truncation by CD26/DPPIV, Mig, but not IP-10
or I-TAC, retained its rather weak calcium-signaling potency
through CXCR3.
Binding properties of intact and CD26/DPP IV–truncated
CXCR3 ligands
The capacity of truncated IP-10 to compete for binding of
125I-labeled intact I-TAC to peripheral blood–derived mononuclear
cells was signiﬁcantly decreased (Figure 5). 125I-labeled intact
I-TAC was preferred over 125I-labeled intact IP-10 for the binding
studies, because the commercially available 125I-labeled IP-10 has
the extra NH2-terminal methionine. At concentrations of 100 nM,
IP-10(3-77) displaced only 49% of the labeled I-TAC from the
cells, whereas the displacement with 100 nM intact IP-10 was 88%.
A comparable difference in binding competition capacity with
125I-labeled I-TAC to mononuclear cells was observed between
intact and truncated I-TAC. On CXCR3-transfected cells, the
binding afﬁnity of IP-10(3-77) and I-TAC(3-73) was also clearly
reduced (Figure 6). No signiﬁcant difference in binding competi-
tion capacity to mononuclear cells was observed between both Mig
forms although a tendency for reduced binding potency for the
truncated Mig was observed. In addition, intact and truncated Mig
could not signiﬁcantly compete for 125I-I-TAC binding to
CXCR3-transfected cells.
Calcium desensitization and chemotaxis antagonism with
truncated CXCR3 ligands
The CXCR3-transfected CHO cells were used to investigate
whetherinactiveCD26/DPPIV–truncatedIP-10(3-77)andI-TAC(3-
73) could desensitize calcium signaling through CXCR3. Addition
Figure 3. Comparison of the chemotactic activity of intact and truncated
chemokines on CXCR3-transfected cells. Met-IP-10 (ﬁlled squares), intact (ﬁlled
symbols), and CD26/DPP IV–truncated (open symbols) IP-10 (diamonds), Mig
(circles), and I-TAC (triangles) were tested for their ability to induce a chemotactic
response on CXCR3-transfected CHO cells. Results represent the mean (6 SEM)
chemotactic index of 4 or more independent experiments. The Student t test was
used for statistical analysis (* 5 P , .1; ** 5 P , .05; *** 5 P , .01 for a positive
chemotactic response compared to buffer controls).
Figure 2. Effect of CD26/DPP IV on the lymphocyte chemotactic activity
of IP-10. The chemotactic activity of Met-IP-10 (ﬁlled squares), intact (ﬁlled dia-
monds), and CD26/DPP IV–truncated (open diamonds) IP-10 for PHA-stimulated (A)
or anti-CD3–stimulated (B) lymphocytes was measured in the Boyden chamber
assay. Results represent the mean (6 SEM) chemotactic index of 4 or more
independent experiments with cells from different donors. The Student t test was
used for statistical analysis (* 5 P , .1; ** 5 P , .05; *** 5 P , .01 for a signiﬁcantly
positive chemotactic response compared to buffer controls).
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the CXCR3-transfected cells resulted in an increase in [Ca11]i of at
least 100 nM (Figure 4). When 100 seconds prior to these stimuli,
10 nM of inactive IP-10(3-77) or 3 nM of inactive I-TAC(3-73) was
added to the cells, the increase in [Ca11]i was reduced by 30% to
40% (Table 2). Thus, truncated inactive CXCR3 ligands partially
desensitize CXCR3 in calcium-signaling experiments.
Because IP-10(3-77) and I-TAC(3-73) failed to induce
chemotactic and calcium-signaling responses, but retained some
receptor-binding properties, these truncated chemokines were
tested as antagonists in chemotaxis assays on CXCR3-
transfected cells (Figure 7). Addition of an inactive concentra-
tion of IP-10(3-77) (30 nM) to the lower well of the Boyden
chamber resulted in 70% reduction in chemotactic response
toward 30 nM intact IP-10 and in complete inhibition of the
chemotactic activity of 10 nM intact IP-10. However, truncated
IP-10 failed to inhibit the chemotactic response toward compa-
rable concentrations of intact I-TAC. In contrast, addition of
truncated I-TAC(3-73) (30 nM) to intact I-TAC (10 nM or 30
nM) resulted in a 50% reduced chemotactic index.
Antiangiogenic activities of IP-10 processed by CD26/DPP IV
When pellets containing 0.3 pmol natural human IL-8 were
implanted into corneal micropockets on rabbit eyes, the induced
neovascularization was maximal between days 5 and 7. Maximal
inhibition of the angiogenic effect of IL-8 (0.3 pmol) was obtained
by addition of 1 pmol intact IP-10 (Figure 8). CD26-truncated
IP-10(3-77) equally inhibited IL-8–induced angiogenesis.At 1 and
3 pmol/pellet, no signiﬁcant differences (Mann-Whitney U test,
P . .2) between the antiangiogenic activities of intact and trun-
cated IP-10 were observed. Comparable results were obtained
when intact Mig(1-103) or CD26-truncated Mig(3-103) were used
as angiogenesis inhibitors. Both intact and truncated Mig inhibited
IL-8–induced angiogenesis. These data indicate that, in contrast to
the inﬂammatory effect (chemotaxis), the angiostatic potential of
IP-10 and Mig is either not mediated through CXCR3 or implicates
alternative CXCR3-triggered signal transduction pathways.
Discussion
During the past 2 decades, more than 50 human chemokines have
been identiﬁed. Chemokines and chemokine receptors form a
complex network that controls leukocyte migration during normal
cell homing as well as inﬂammatory processes. The receptor
speciﬁcity of chemokines determines the pattern of target cells.The
expression of chemokines and chemokine receptors is regulated at
the transcriptional level by different inducers. IFN-g, a prototypic
Th1 cytokine, has been reported to enhance the production of the
non-ELRCXC chemokines IP-10, Mig, and I-TAC,7,35-38 but it
down-regulates the production of neutrophil chemotactic chemo-
kines such as the ELRCXC chemokines IL-8 and ENA-78.39 All 3
IFN-inducible non-ELRCXC chemokines interact with CXCR3.
This receptor is highly expressed on activated memory T cells
(CD45RO1 cells) and has been detected on a small portion of B
cells and NK cells.5,11 Higher CXCR3 expression levels were Figure 4. Comparison of the calcium-mobilizing capacity of intact and trun-
cated chemokines on CXCR3-transfected cells. Met-IP-10 (ﬁlled squares), intact
(ﬁlled symbols), and CD26/DPP IV–truncated (open symbols) IP-10 (diamonds), Mig
(circles), and I-TAC (triangles) were tested for their ability to increase the [Ca11]i in
CXCR3-transfected CHO cells. Results represent the mean (6 SEM) increase of the
[Ca11]i of 5 or more independent experiments. The detection limit for the increase of
the [Ca11]i is indicated by the dashed line.
Figure 5. Receptor-binding properties of intact and CD26/DPP IV–truncated
CXCR3 agonists on mononuclear cells. Intact (ﬁlled symbols) and CD26/DPP
IV–truncated (open symbols) IP-10 (diamonds), I-TAC (triangles), and Mig (circles)
were tested for their ability to compete for 125I-labeled I-TAC binding to peripheral
blood–derived mononuclear cells. Results represent the mean (6 SEM) percent of
125I-I-TAC that binds to the cells compared to the amount of labeled I-TAC that binds
the cells without addition of cold ligands (3 or more independent experiments). The
Student t test was used for statistical analysis (** 5 P , .05 for a signiﬁcant
difference between the intact and truncated chemokines).
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been reported to attract Th1 but not Th2 cells.9 Additional
regulatorymechanismsofchemokineactivityandreceptorspeciﬁc-
ity were shown at the posttranscriptional level, mainly by NH2-
terminal chemokine processing. For example, limited NH2-
terminal truncation of IL-8 (eg, by gelatinase B) enhanced its
chemotactic potency, whereas platelet basic protein was found to
become chemotactic only when truncated into NAP-2.21,40 In
contrast, small modiﬁcations of the NH2-terminal residues of
MCP-1, MCP-2, and MCP-3 decreased the biologic activity of
these CC chemokines.22,23
Recently, the highly speciﬁc protease CD26/DPP IV has been
reported to process a number of chemokines at the NH2 terminus
with different effects on their chemotactic and antiviral activi-
ties.24,26 CD26/DPP IV is expressed on a wide variety of cells
including ﬁbroblasts and epithelial and endothelial cells. Moreover,
CD26/DPP IV expression on CD45RO1 Th1 lymphocytes is
further increased during activation. This protease cleaves GCP-2,
SDF-1,RANTES,eotaxin,macrophage-derivedchemokine(MDC),
and the macrophage inﬂammatory protein-1a (MIP-1a) isoform
LD78b into NH2-terminally truncated forms.24,26Although MCP-1,
MCP-2, MCP-3, and MIP-1b also possess the prerequisite penulti-
mate proline, they are not processed by CD26/DPP IV. MCPs are
protected from the proteolytic activity by their NH2-terminal
pyroglutamic acid.41 Here we report that CD26/DPP IV is able to
efﬁciently cleave the NH2-terminal dipeptide of all 3 CXCR3
ligands, IP-10, Mig, and I-TAC. Time-course experiments showed
that with physiologic serum concentrations of CD26/DPP IV, the
majority of the chemokine is processed within a few minutes even
when high concentrations of chemokine (5 mM) are present. This
rapid processing of the CXCR3 ligands at physiologic concentra-
tions of CD26/DPP IV (25 U/L) is indicative of an important
functional role of the interaction between this ubiquitous protease
and these chemokines. Recently, we compared the kinetic parame-
ters for the truncation of different chemokines by CD26/DPP IV.
IP-10 and I-TAC, together with the CXC chemokine SDF-1a and
the CC chemokine MDC, were the best substrates for this protease
with a half-life of less than 10 minutes at physiologic CD26/DPP
IV concentrations.42
The chemotactic potency of the CXC chemokine SDF-1 and of
the CC chemokines RANTES, eotaxin, and MDC was drastically
reduced on NH2-terminal truncation by CD26/DPP IV.26 Accord-
ingly, the binding afﬁnity and calcium-signaling capacity of
truncated SDF-1, eotaxin, and MDC for their respective receptors
CXCR4, CCR3, and CCR4 decreased. Moreover, inhibition of
CD26/DPP IV resulted in prolonged protein kinase B activation by
SDF-1 in T cells.43 In contrast, treatment of the CC chemokine
LD78b with CD26/DPP IV generated a highly potent monocyte
and lymphocyte chemoattractant that retained strong anti–HIV-1
Figure 6. Receptor binding properties of intact and CD26/DPP IV–truncated
CXCR3 agonists on CXCR3-transfected cells. Intact (ﬁlled symbols) and CD26/
DPP IV–truncated (open symbols) IP-10 (diamonds), I-TAC (triangles), and Mig
(circles) were tested for their ability to compete for 125I-labeled I-TAC binding to
CXCR3-transfected CHO cells. Results represent the mean (6 SEM) percent of
125I-I-TAC that binds to the cells compared to the amount of labeled I-TAC that binds
the cells without addition of cold ligands (3 or more independent experiments). The
Student t test was used for statistical analysis (** 5 P , .05 and *** 5 P , .01 for a
signiﬁcant difference between the intact and truncated chemokines).
Figure 7. Inhibition of chemotaxis by truncated IP-10(3-77) and I-TAC(3-73). The
antagonistic activity of CD26/DPP IV–truncated IP-10 and I-TAC was tested on
CXCR3-transfected cells in the Boyden microchamber. Intact agonistic IP-10 or
I-TAC (at 10 or 30 nM) was added with or without 30 nM truncated chemokine
[IP-10(3-77) or I-TAC(3-73)] to the bottom well of the chemotaxis chamber. Results
represent the mean (6 SEM) percent inhibition of the chemotactic index (CI) toward
intact chemokine alone from 4 to 5 independent experiments. The Student t test was
used for statistical analysis comparing the CI with and without addition of truncated
chemokine (** 5 P , .05; *** 5 P , .01).
Table 2. Desensitization of CXCR3 by CD26/DPP IV–truncated chemokines
First stimulus* Second stimulus Desensitization† (%)
10 nM IP-10(3-77) 1 nM IP-10(1-77) 37
0.3 nM IP-10(1-77) 39
50 nM Mig(1-103) 34
0.3 nM I-TAC(1-73) 29
3 nM I-TAC(3-73) 0.3 nM IP-10(1-77) 31
0.3 nM I-TAC(1-73) 32
*The ﬁrst stimulus did not induce an increase of the intracellular calcium
concentration.
†Compared to CXCR3-transfected CHO cells that were treated with calcium
buffer as a ﬁrst stimulus (average percent desensitization of 2-4 independent
experiments).
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IV described here resulted in 30-fold reduced lymphocyte chemotactic
activity.All 3 truncated CXCR3 ligands, that is, IP-10, Mig, and I-TAC,
lost chemotactic activity mediated through CXCR3. The calcium-
signaling capacity of IP-10 and I-TAC through CXCR3 was also
abolished on NH2-terminal truncation. CD26/DPP IV–truncated IP-10
and I-TAC retained weak CXCR3-binding properties, but higher doses
of the truncated variant versus intact chemokine were necessary to
remove 125I-I-TAC from its receptor. Finally, on CXCR3-transfected
cells, truncated IP-10 acted as a chemotaxis antagonist for intact IP-10
but not for intact I-TAC. In contrast, truncated I-TAC partially inhibited
the chemotactic response toward intact I-TAC. These results are not
surprising because I-TAC is known to be a stronger CXCR3 ligand that
binds, in contrast to IP-10 and Mig, to both coupled and uncoupled
CXCR3 receptors.45
So far, limited information is available on the role of CXCR3 in
the angiostatic activity of IP-10. The reported expression of
CXCR3 on microvascular endothelial cells is dependent on the cell
cycle.19,20 Only proliferating, and not resting, microvascular endo-
thelial cells are CXCR31. However, no ﬁrm proof of the necessity
of CXCR3 for the antiangiogenic effect of IP-10 and Mig has been
given (eg, in receptor neutralization assays). Surprisingly, CD26/
DPP IV–truncated IP-10 and Mig retained antiangiogenic activity
in the rabbit cornea micropocket model. Consequently, CXCR3-
mediated chemotactic activity and calcium signaling are no prereq-
uisitesfortheangiostaticactivity.Recently,alsothemurine,butnot
the human, CC chemokine 6C-kine (CCL21) has been reported to
inhibit metastasis of human lung cancer cells in severe combined
immunodeﬁcient mice and to reduce tumor vascularity.46 Because
murine, and not human, 6C-kine is a ligand for human CXCR3,
these results suggest that CXCR3 is directly involved in the
antiangiogenic effects of its ligands IP-10 and Mig. Thus, if
CXCR3 is required for the antiangiogenic activity of IP-10, then
the antiangiogenic and leukocyte chemotactic pathways use differ-
ent signal transduction mechanisms. In fact, recent reports have
shown that depending on the cell type multiple signal transduction
pathways may be activated through CXCR3 including extracellular
signal-regulated kinase (ERK), Src, and phosphatidylinositol-3
kinase (PI3K) signal cascades.47,48 Our results suggest that trun-
cated IP-10 and Mig could activate some (those that are important
for the antiangiogenic effect) but not all CXCR3 signal transduc-
tion pathways.
Because IFN-g production (the main inducer of the CXCR3
ligands), CD26/DPP IV expression, and CXCR3 expression are
hallmarks for activated memory Th1 cells, processing of the 3
chemokines by CD26/DPP IV may constitute an important physi-
ologic regulatory mechanism during the attraction of leukocytes in
a Th1 response. Indeed, in the case of a typical Th1 response, it is
crucial to dampen the cellular reaction after inﬂux of sufﬁcient
cells. Chemoattracted Th1 lymphocytes, laden with CD26/DPP IV,
cleave the angiostatic chemokines IP-10, Mig, and I-TAC, and the
angiogenic chemokine SDF-1a, resulting in down-modulation of
their chemotactic activity. If the angiostatic effects would also be
reduced, then the balance would be in favor of angiogenesis, which
may bring the local vessels and the circulating leukocytes closer to
the Th1 response site. Obviously, the latter effect does not occur
and angiostasis thus helps to keep the circulating lymphocytes out
of the ﬁeld of attraction and to halt the inﬂammation. As a
consequence, the balance between CD26/DPP IV activity and
CXCR3 ligands may play an important role in disease processes
such as multiple sclerosis,49-51 B-cell leukemia,52 hepatocellular
carcinoma,53 and skin diseases36,54,55 in which disease expression of
CXCR3 and its ligands have been reported.
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